Skip to content

Effect of Risperidone on psychosis

Effect of Risperidone on reducing the symptoms of methamphetamine induced psychosis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT201311199858N5
Enrollment
32
Registered
2013-11-30
Start date
2013-12-01
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

?????? ???? ?? ???? ????. Mental and behavioural disorders due to use of other stimulants, including caffeine

Interventions

After determining the severity of symptoms and scoring by the physician, Tablet Risperidone 1 mg daily with therapeutic dosage of 1 to 3 mg daily will be administered for 1 week..
Treatment - Drugs
After determining the severity of symptoms and scoring by the physician, Tablet Risperidone 1 mg daily with therapeutic dosage of 1 to 3 mg daily will be administered for 1 week.

Sponsors

Vice chancellor for research, Tabriz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1. At least 18 years of age 2. Diagnosis of methamphetamine induced psychosis with structured clinical interview SCID by the approval of a psychiatrist or a psychologist. 3. No anti-psychotic drug use. 4. No other psychological disorders. Exclusion criteria: Patient's unwillingness to continue to participate in the study.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Negative symptoms of psychosis. Timepoint: before intervention and 1 week after intervention. Method of measurement: Scale for the Assessment of negative Symptoms (SANS).;Positive symptoms of psychosis. Timepoint: before intervention and 1 week after intervention. Method of measurement: Scale for the Assessment of Positive Symptoms (SAPS).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Arash Mohagheghi

Clinical Psychiatry Research Center

mohaggheghi.a@gmail.com+98 41 1380 3353

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026